Comparison of the Hypamylasemic Effects of Erythropoietin and U-74389G

Research Article

J Bacteriol Mycol. 2020; 7(4): 1136.

Comparison of the Hypamylasemic Effects of Erythropoietin and U-74389G

Constantinos T1*, Panoulis C2, Triantafyllou A3, Zografos CG4, Gerakis E5, Gerakis S5 and Papalois A6

11Department of Gynecology, Anticancer Hospital of Thessaloniki “Theageneio” Thessaloniki, Hellas

2Department of Obstetrics & Gynecology, Aretaieion Hospital, Athens University, Athens, Attiki, Hellas

3Department of Biologic Chemistry, Athens University, Athens, Attiki, Hellas

4Department of Surgery, Ippokrateion General Hospital, Athens University, Athens, Attiki, Hellas

5Experimental Research Centre ELPEN Pharmaceuticals, S.A. Inc., Co., Pikermi, Attiki, Hellas

6Experimental, Educational and Research Center ELPEN European University Cyprus, School of Medicine, Attiki, Hellas

*Corresponding author: Tsompos Constantinos, Department of Gynecology, Anticancer Hospital of Thessaloniki, Theageneio, 2 Alexandrou Symeonidi Street, Thessaloniki 54007, Hellas

Received: May 17, 2020; Accepted: June 15, 2020; Published: June 22, 2020


Aim: This study calculated the effects on serum Amylase (A) levels, after treatment with either of 2 drugs: the Erythropoietin (Epo) and the antioxidant Lazaroid (L) drug U-74389G. The calculation was based on the results of 2 preliminary studies, each one of which estimated the certain influence, after the respective drug usage in an induced Ischemia Reperfusion (IR) animal experiment.

Materials and Methods: The 2 main experimental endpoints at which the serum A levels were evaluated was the 60th reperfusion min (for the groups A, C and E) and the 120th reperfusion min (for the groups B, D and F). Specially, the groups A and B were processed without drugs, the groups C and D after Epo administration; whereas the groups E and F after the L administration.

Results: The first preliminary study of Epo presented a non significant hypamylasemic effect by 0.86%+1.14% (p-value=0.4430). However, the second preliminary study of U-74389G presented a significant hypamylasemic effect by 3.92%+1.06% (p-value=0.0005). These 2 studies were co-evaluated since they came from the same experimental setting. The outcome of the co-evaluation was that L is just by 4.561391-fold [4.553287 - 4.569509] more hypamylasemic than Epo (p-value=0.0000).

Conclusions: The anti-oxidant capacities of U-74389G ascribe just 4.561391-fold [4.553287 - 4.569509] more hypamylasemic effects than Epo (p-value=0.0000). However, a separate study is required for insulin and diabetes.

Keywords: Ischemia; Erythropoietin; U-74389G; Serum Amylase Levels; Reperfusion


The Lazaroid U-74389G (L) may be not famous for its hypamylasemic [1]. Capacity (p-value=0.0005). U-74389G as a novel antioxidant factor, implicates exactly only 263 published studies. The Ischemia Reperfusion (IR) type of experiments was noted in 19.01% of these studies. A tissue protective feature of U-74389G was obvious in these IR studies. The U-74389G chemically known as 21-[4-(2,6-di-1- pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-pregna-1,4,9(11)-triene- 3,20-dione maleate salt is an antioxidant complex, which prevents the lipid peroxidation either iron-dependent, or arachidonic acidinduced one. Animal kidney, liver, brain microvascular endothelial cells monolayers and heart models were protected by U-74389G after IR injury. U-74389G also attenuates the leukocytes; downregulates the proinflammatory gene; treats the endotoxin shock; produces cytokine; enhances the mononuclear immunity; protects the endothelium and presents antishock property.

Erythropoietin (Epo) even if is not famous for its hypamylasemic [2]. Action (p-value=0.4430), it can be used as a reference drug for comparison with U-74389G. Although Epo is met in over 31,593 published biomedical studies, only a 3.7% of them negotiate the known type of IR experiments. Nevertheless, Epo as a cytokine, it is worth of being studied about its effects on serum amylase (A) levels too. This experimental work tried to compare the effects of the above drugs on a rat induced IR protocol. They were tested by calculating the serum A levels alterations.

Materials and Methods

Animal preparation

The Vet licenses under 3693/12-11- 2010 & 14/10-1-2012 numbers, the granting company and the experiment location are mentioned in preliminary references [1,2]. The human animal care of Albino female Wistar rats, the 7 days pre-experimental ad libitum diet, the non-stop intra-experimental anesthesiologic techniques, the acidometry, the electrocardiogram, the oxygen supply and postexperimental euthanasia are also described in preliminary references. Rats were 16-18 weeks old. They were randomly assigned to six (6) groups consisted in N=10. The stage of 45 min hypoxia was common for all 6 groups. Afterwards, reperfusion of 60 min was followed in group A; reperfusion of 120 min in group B; immediate Epo intravenous (IV) administration and reperfusion of 60 min in group C; immediate Epo IV administration and reperfusion of 120 min in group D; immediate U-74389G IV administration and reperfusion of 60 min in group E; and immediate U-74389G IV administration and reperfusion of 120 min in group F. The dose height assessment for both drugs are described at preliminary studies as 10 mg/Kg body mass. over renal arteries with forceps for 45 min. The clamp removal was restoring the inferior aorta patency and reperfusion. After exclusion of the blood flow, the protocol of IR was applied, as described above for each experimental group. The drugs were administered at the time of reperfusion; through inferior vena cava catheter. The A levels were determined at 60th min of reperfusion (for A, C and E groups) and at 120th min of reperfusion (for B, D and F groups). Along, powerful relation was rised between A values with animals’ mass (p-value=0.0167); so as to predicted amylase values for rats’ weights were used.

Statistical analysis

Table 1 presents the (%) hypamylasemic influence of Epo regarding reoxygenation time. Also, Table 2 presents the (%) hypamylasemic influence of U-74389G regarding reperfusion time. Chi-square tests were applied using the ratios which produced the (%) results per endpoint. The outcomes of chi-square tests are depicted at Table 3.